Qiagen (QGEN) Set to Announce Quarterly Earnings on Monday

Qiagen (NYSE:QGEN) will issue its quarterly earnings data after the market closes on Monday, April 29th. Analysts expect the company to announce earnings of $0.44 per share for the quarter. Qiagen has set its FY 2024 guidance at 2.100- EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $0.55 earnings per share for the quarter, meeting the consensus estimate of $0.55. Qiagen had a net margin of 17.37% and a return on equity of 12.99%. The company had revenue of $509.00 million during the quarter, compared to analyst estimates of $500.77 million. During the same quarter last year, the firm posted $0.53 EPS. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Stock Performance

NYSE:QGEN opened at $40.00 on Monday. Qiagen has a twelve month low of $34.74 and a twelve month high of $47.70. The company has a current ratio of 1.99, a quick ratio of 1.62 and a debt-to-equity ratio of 0.24. The company has a 50-day moving average of $42.74 and a 200-day moving average of $42.68. The firm has a market cap of $9.13 billion, a price-to-earnings ratio of 26.44, a price-to-earnings-growth ratio of 3.37 and a beta of 0.41.

Institutional Trading of Qiagen

A number of hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its position in Qiagen by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 81,080 shares of the company’s stock valued at $3,522,000 after acquiring an additional 7,739 shares in the last quarter. SageView Advisory Group LLC bought a new position in Qiagen during the fourth quarter valued at approximately $325,000. GSA Capital Partners LLP bought a new position in Qiagen during the fourth quarter valued at approximately $1,230,000. Legal & General Group Plc raised its position in shares of Qiagen by 16.5% in the fourth quarter. Legal & General Group Plc now owns 2,356,260 shares of the company’s stock valued at $102,511,000 after purchasing an additional 332,888 shares during the period. Finally, Barclays PLC raised its position in shares of Qiagen by 10.1% in the fourth quarter. Barclays PLC now owns 1,352,420 shares of the company’s stock valued at $58,737,000 after purchasing an additional 123,913 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have commented on QGEN. Morgan Stanley upgraded shares of Qiagen from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $49.48 to $51.00 in a report on Friday, February 16th. Citigroup decreased their target price on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a report on Thursday, February 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a report on Thursday, February 8th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.69.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.